<DOC>
	<DOCNO>NCT00991159</DOCNO>
	<brief_summary>The study design determine safety tolerability RN316 administer intravenously healthy adult subject . This first time RN316 give human .</brief_summary>
	<brief_title>A Study To Access The Safety And Tolerability Of RN316 ( PF-04950615 ) When Administered To Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy , ambulatory men woman ( nonchildbearing potential ) age 18 70 inclusive . Baseline total cholesterol ≥ 200 mg/dl , baseline LDL ≥ 130 mg/dl . BMI 18.5 35 , body weight ≤150 kg , inclusive . Evidence clinically significant disease may increase risk subject study participation interfere interpretation result . Secondary hyperlipidemia . Subjects take lipid lower compound within past 12 month prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Endocrinology ; Hypercholesterolemia ; Hyperlipidemia ; Lipid Metabolism Disorders RN316 PF-04950615</keyword>
</DOC>